Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 8;12(8):1568–1578. doi: 10.1158/1535-7163.MCT-12-1010

Figure 4. Bortezomib inhibits NF-κB in HRC cells.

Figure 4

(A) Nuclear extracts from unstimulated HRC cell lines were pre-incubated with the indicated anti-NF-κB subunit antibodies and supershift of NF-κB complexes was examined by EMSA using radiolabeled NF-κB consensus or mutant oligonucleotides. (Ctrl. = control extract without antibody) Visibly-supershifted P50-containing complexes are indicated with an asterisk. The anti-RelA–supershifted complex is not seen in these autoradiograms as it can often be too large to enter the gel (12). (B) HRC cell lines were treated with bortezomib for 12 h, and nuclear extracts prepared from these cells were examined for binding to a radiolabeled NF-κB probe by EMSA. (C) NF-κB bands in the EMSA autoradiograms shown in (B) were densitometrically quantified by Image J analysis.